MedKoo Cat#: 561646 | Name: Ritanserin
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ritanserin (R 55667) is a selective and potent serotonin-2 antagonist. Ritanserin acts as a selective 5-HT2A (Ki = 0.45 nM) and 5-HT2C receptor (Ki = 0.71 nM) antagonist.

Chemical Structure

Ritanserin
Ritanserin
CAS#87051-43-2 (free base)

Theoretical Analysis

MedKoo Cat#: 561646

Name: Ritanserin

CAS#: 87051-43-2 (free base)

Chemical Formula: C27H25F2N3OS

Exact Mass: 477.1686

Molecular Weight: 477.57

Elemental Analysis: C, 67.91; H, 5.28; F, 7.96; N, 8.80; O, 3.35; S, 6.71

Price and Availability

Size Price Availability Quantity
25mg USD 250.00 2 Weeks
50mg USD 450.00 2 Weeks
100mg USD 750.00 2 Weeks
200mg USD 1,250.00 2 Weeks
500mg USD 2,850.00 2 Weeks
1g USD 4,250.00 2 Weeks
2g USD 7,450.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Synonym
Ritanserin; R-55667; R 55667; R55667;
IUPAC/Chemical Name
6-[2-[4-[Bis(4-fluorophenyl)methylidene]piperidin-1-yl]ethyl]-7-methyl-[1,3]thiazolo[3,2-a]pyrimidin-5-one
InChi Key
JUQLTPCYUFPYKE-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H25F2N3OS/c1-18-24(26(33)32-16-17-34-27(32)30-18)12-15-31-13-10-21(11-14-31)25(19-2-6-22(28)7-3-19)20-4-8-23(29)9-5-20/h2-9,16-17H,10-15H2,1H3
SMILES Code
O=C1C(CCN2CC/C(CC2)=C(C3=CC=C(F)C=C3)\C4=CC=C(F)C=C4)=C(C)N=C5N1C=CS5
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
Ritanserin is a highly potent, relatively selective, orally active, long acting antagonist of 5-HT2 receptor, with an IC50 of 0.9 nM. It is less active on histamine H1 (IC50 35 nM), dopamine D2 (IC50 70 nM), adrenergic α1 (IC50 97 nM), and adrenergic α2 receptors (IC 50 150 nM).
In vitro activity:
Ritanserin could be effective in preventing or treating existing blindness by restoring corneal transparency. Ritanserin can rescue PAX6 haploinsufficiency of mutant limbal cells, defective cell migration, and PAX6-target gene expression. Ritanserin activates PAX6 production through the selective inactivation of the MEK/ERK signaling pathway. Reference: Biochem Biophys Res Commun. 2021 Dec 10;582:100-104. https://pubmed.ncbi.nlm.nih.gov/34700241/
In vivo activity:
This study suggests a differential role of 5HT(2A/2C) and 5HT(3) receptors during spatial learning that ritanserin improves rat performance in spatial discrimination task. Compared with the control group, ritanserin significantly reduced the escape latency and traveled distance of swimming to platform in rats who had their hippocampus injected with ritanserin. Reference: Behav Brain Res. 2005 Feb 28;157(2):205-10. https://pubmed.ncbi.nlm.nih.gov/15639171/
Solvent mg/mL mM
Solubility
DMSO 52.4 110.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 477.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Boroda S, Niccum M, Raje V, Purow BW, Harris TE. Dual activities of ritanserin and R59022 as DGKα inhibitors and serotonin receptor antagonists. Biochem Pharmacol. 2017 Jan 1;123:29-39. doi: 10.1016/j.bcp.2016.10.011. Epub 2016 Oct 28. PMID: 27974147; PMCID: PMC5164959. 2. Oved K, Zennaro L, Dorot O, Zerbib J, Frank E, Roux LN, Bremond-Gignac D, Pichinuk E, Aberdam D. Ritanserin, a potent serotonin 2A receptor antagonist, represses MEK/ERK signalling pathway to restore PAX6 production and function in aniridia-like cellular model. Biochem Biophys Res Commun. 2021 Dec 10;582:100-104. doi: 10.1016/j.bbrc.2021.10.036. Epub 2021 Oct 16. PMID: 34700241. 3. Naghdi N, Harooni HE. The effect of intrahippocampal injections of ritanserin (5HT2A/2C antagonist) and granisetron (5HT3 antagonist) on learning as assessed in the spatial version of the water maze. Behav Brain Res. 2005 Feb 28;157(2):205-10. doi: 10.1016/j.bbr.2004.06.024. PMID: 15639171. 4. İlkaya F, Yüce M, Ağrı AE, Güzel H, Balcı H, Uçar F, Babadağı Z, Müjdeci M, Mutlu E. The combination of agomelatine and ritanserin exerts a synergistic interaction in passive avoidance task. Hum Exp Toxicol. 2015 Aug;34(8):787-95. doi: 10.1177/0960327114559613. Epub 2014 Nov 12. PMID: 25394903.
In vitro protocol:
1. Boroda S, Niccum M, Raje V, Purow BW, Harris TE. Dual activities of ritanserin and R59022 as DGKα inhibitors and serotonin receptor antagonists. Biochem Pharmacol. 2017 Jan 1;123:29-39. doi: 10.1016/j.bcp.2016.10.011. Epub 2016 Oct 28. PMID: 27974147; PMCID: PMC5164959. 2. Oved K, Zennaro L, Dorot O, Zerbib J, Frank E, Roux LN, Bremond-Gignac D, Pichinuk E, Aberdam D. Ritanserin, a potent serotonin 2A receptor antagonist, represses MEK/ERK signalling pathway to restore PAX6 production and function in aniridia-like cellular model. Biochem Biophys Res Commun. 2021 Dec 10;582:100-104. doi: 10.1016/j.bbrc.2021.10.036. Epub 2021 Oct 16. PMID: 34700241.
In vivo protocol:
1. Naghdi N, Harooni HE. The effect of intrahippocampal injections of ritanserin (5HT2A/2C antagonist) and granisetron (5HT3 antagonist) on learning as assessed in the spatial version of the water maze. Behav Brain Res. 2005 Feb 28;157(2):205-10. doi: 10.1016/j.bbr.2004.06.024. PMID: 15639171. 2. İlkaya F, Yüce M, Ağrı AE, Güzel H, Balcı H, Uçar F, Babadağı Z, Müjdeci M, Mutlu E. The combination of agomelatine and ritanserin exerts a synergistic interaction in passive avoidance task. Hum Exp Toxicol. 2015 Aug;34(8):787-95. doi: 10.1177/0960327114559613. Epub 2014 Nov 12. PMID: 25394903.
1: Tan J, Zhong M, Hu Y, Pan G, Yao J, Tang Y, Duan H, Jiang Y, Shan W, Lin J, Liu Y, Huang J, Zheng H, Zhou Y, Fu G, Li Z, Xu B, Zha J. Ritanserin suppresses acute myeloid leukemia by inhibiting DGKα to downregulate phospholipase D and the Jak-Stat/MAPK pathway. Discov Oncol. 2023 Jul 1;14(1):118. doi: 10.1007/s12672-023-00737-9. PMID: 37392305; PMCID: PMC10314883. 2: Zhou D, Liu T, Rao X, Jie X, Chen Y, Wu Z, Deng H, Zhang D, Wang J, Wu G. Targeting diacylglycerol kinase α impairs lung tumorigenesis by inhibiting cyclin D3. Thorac Cancer. 2023 May;14(13):1179-1191. doi: 10.1111/1759-7714.14851. Epub 2023 Mar 25. PMID: 36965165; PMCID: PMC10151139. 3: Jiang SS, Gong MN, Rao W, Chai W, Chen WZ, Zhang X, Nie HB, Xu RS. 5-Hydroxytryptamine: a potential therapeutic target in amyotrophic lateral sclerosis. Neural Regen Res. 2023 Sep;18(9):2047-2055. doi: 10.4103/1673-5374.367929. PMID: 36926731; PMCID: PMC10233787. 4: Afolabi JM, Michael OS, Falayi OO, Kanthakumar P, Mankuzhy PD, Soni H, Adebiyi A. Activation of renal vascular smooth muscle TRPV4 channels by 5-hydroxytryptamine impairs kidney function in neonatal pigs. Microvasc Res. 2023 Jul;148:104516. doi: 10.1016/j.mvr.2023.104516. Epub 2023 Mar 6. Erratum in: Microvasc Res. 2024 Jul;154:104696. doi: 10.1016/j.mvr.2024.104696. PMID: 36889668; PMCID: PMC10258165. 5: La Marca JE, Ely RW, Diepstraten ST, Burke P, Kelly GL, Humbert PO, Richardson HE. A Drosophila chemical screen reveals synergistic effect of MEK and DGKα inhibition in Ras-driven cancer. Dis Model Mech. 2023 Mar 1;16(3):dmm049769. doi: 10.1242/dmm.049769. Epub 2023 Apr 3. PMID: 36861754; PMCID: PMC10110402. 6: Yamamoto R, Ito T, Furuyama T, Ono M, Kato N. 5-HT and α-m-5-HT attenuate excitatory synaptic transmissions onto the lateral amygdala principal neurons via presynaptic 5-HT1B receptors. Biochem Biophys Res Commun. 2022 Oct 8;624:28-34. doi: 10.1016/j.bbrc.2022.07.076. Epub 2022 Jul 31. PMID: 35932576. 7: Li YX, Li JH, Guo Y, Tao ZY, Qin SH, Traub RJ, An H, Cao DY. Oxytocin inhibits hindpaw hyperalgesia induced by orofacial inflammation combined with stress. Mol Pain. 2022 Jan-Dec;18:17448069221089591. doi: 10.1177/17448069221089591. PMID: 35266833; PMCID: PMC9047792. 8: Kusljic S, van den Buuse M, Gogos A. Reassessment of amphetamine- and phencyclidine-induced locomotor hyperactivity as a model of psychosis-like behavior in rats. J Integr Neurosci. 2022 Jan 28;21(1):17. doi: 10.31083/j.jin2101017. PMID: 35164453. 9: García-Pedraza JÁ, Fernández-González JF, López C, Martín ML, Alarcón- Torrecillas C, Rodríguez-Barbero A, Morán A, García-Domingo M. Oral fluoxetine treatment changes serotonergic sympatho-regulation in experimental type 1 diabetes. Life Sci. 2022 Mar 15;293:120335. doi: 10.1016/j.lfs.2022.120335. Epub 2022 Jan 18. PMID: 35051421. 10: Granade ME, Manigat LC, Lemke MC, Purow BW, Harris TE. Identification of ritanserin analogs that display DGK isoform specificity. Biochem Pharmacol. 2022 Mar;197:114908. doi: 10.1016/j.bcp.2022.114908. Epub 2022 Jan 6. PMID: 34999054; PMCID: PMC8858877. 11: Oved K, Zennaro L, Dorot O, Zerbib J, Frank E, Roux LN, Bremond-Gignac D, Pichinuk E, Aberdam D. Ritanserin, a potent serotonin 2A receptor antagonist, represses MEK/ERK signalling pathway to restore PAX6 production and function in aniridia-like cellular model. Biochem Biophys Res Commun. 2021 Dec 10;582:100-104. doi: 10.1016/j.bbrc.2021.10.036. Epub 2021 Oct 16. PMID: 34700241. 12: García-Pedraza JÁ, López C, Fernández-González JF, Martín ML, Morán A, García-Domingo M. Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment. J Pharmacol Sci. 2021 Sep;147(1):48-57. doi: 10.1016/j.jphs.2021.05.008. Epub 2021 May 23. PMID: 34294372. 13: Kovalenko A, Sanin A, Kosmas K, Zhang L, Wang J, Akl EW, Giannikou K, Probst CK, Hougard TR, Rue RW, Krymskaya VP, Asara JM, Lam HC, Kwiatkowski DJ, Henske EP, Filippakis H. Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex. Cancer Res. 2021 Apr 15;81(8):2086-2100. doi: 10.1158/0008-5472.CAN-20-2218. Epub 2021 Feb 16. PMID: 33593821; PMCID: PMC8137542. 14: Okada T, Shioda K, Makiguchi A, Suda S. Risperidone and 5-HT2A Receptor Antagonists Attenuate and Reverse Cocaine-Induced Hyperthermia in Rats. Int J Neuropsychopharmacol. 2020 Dec 29;23(12):811-820. doi: 10.1093/ijnp/pyaa065. PMID: 32821948; PMCID: PMC7770520. 15: Jones MT, Strassnig MT, Harvey PD. Emerging 5-HT receptor antagonists for the treatment of Schizophrenia. Expert Opin Emerg Drugs. 2020 Jun;25(2):189-200. doi: 10.1080/14728214.2020.1773792. Epub 2020 Jun 8. PMID: 32449404. 16: Poyurovsky M, Weizman A. Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists. Drugs. 2020 Jun;80(9):871-882. doi: 10.1007/s40265-020-01312-0. PMID: 32385739. 17: Liu L, Yudin Y, Rohacs T. Diacylglycerol kinases regulate TRPV1 channel activity. J Biol Chem. 2020 Jun 12;295(24):8174-8185. doi: 10.1074/jbc.RA119.012505. Epub 2020 Apr 28. PMID: 32345612; PMCID: PMC7294095. 18: Fusi F, Trezza A, Sgaragli G, Spiga O, Saponara S, Bova S. Ritanserin blocks CaV1.2 channels in rat artery smooth muscles: electrophysiological, functional, and computational studies. Acta Pharmacol Sin. 2020 Sep;41(9):1158-1166. doi: 10.1038/s41401-020-0370-1. Epub 2020 Mar 4. PMID: 32132658; PMCID: PMC7608335. 19: Cervantes-Ramírez V, Canto-Bustos M, Aguilar-Magaña D, Pérez-Padilla EA, Góngora-Alfaro JL, Pineda JC, Atzori M, Salgado H. Citalopram reduces glutamatergic synaptic transmission in the auditory cortex via activation of 5-HT1A receptors. Neuroreport. 2019 Dec 18;30(18):1316-1322. doi: 10.1097/WNR.0000000000001366. PMID: 31714483. 20: Velnati S, Ruffo E, Massarotti A, Talmon M, Varma KSS, Gesu A, Fresu LG, Snow AL, Bertoni A, Capello D, Tron GC, Graziani A, Baldanzi G. Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening. Eur J Med Chem. 2019 Feb 15;164:378-390. doi: 10.1016/j.ejmech.2018.12.061. Epub 2018 Dec 26. PMID: 30611057; PMCID: PMC6599760.